+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Cellular Immunotherapy Market Research Report by Type (CAR T-Cell Therapy, Dendritic Cell Therapy, and NK Cell Therapy), Indication, Technology Type, End-Use, Region - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030

  • PDF Icon

    Report

  • 222 Pages
  • January 2023
  • Region: Global
  • 360iResearch™
  • ID: 5665829
UP TO OFF until Mar 31st 2023
The Global Cellular Immunotherapy Market size was estimated at USD 9,000.43 million in 2022, USD 11,232.35 million in 2023, and is projected to grow at a CAGR of 25.27% to reach USD 54,607.77 million by 2030.

Cumulative Impact of COVID-19:

COVID-19 is an unprecedented global public health emergency that affected almost every industry, and the long-term impacts are projected to reflect on the growth of various end-use industries during the forecast period. This ongoing research amplifies the research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19, considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The dedicated section in the report uncovers a detailed analysis of the impact of COVID-19 and its subsequent variant outbreaks on demand, supply, price, and vendor uptake and provides recommendations for sustainable outcomes. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the Global Cellular Immunotherapy Market.

Cumulative Impact of Russia-Ukraine Conflict:

The publisher continuously monitors and update reports considering unceasing political and economic uncertainty due to the Russia-Ukraine Conflict. Negative impacts are globally foreseen, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected people’s lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on Ukraine and reverberate harsh long-term effects on Russia. The report uncovers the implications for demand-supply balances, pressure on pricing variants, impact on import/export and trading, and short-term recommendations to the Global Cellular Immunotherapy Market considering the current update on the conflict and its global responses.

Cumulative Impact of High Inflation:

The high inflation in developed economies globally has resulted in an overall price surge over the past two years. The cumulatively eroding overall purchasing power is expected to impact developing economies significantly and is considered helpful in numerous ways. The report uncovers the effect of high inflation on the long-term performance of the global economy and provides details on fiscal policies measuring and reducing its short-term impacts on demand/supply, cash flow, and currency exchange. The Global Cellular Immunotherapy Market report delivers the high inflation expectation considering the related impact from cost-push and demand-pull inflation.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make better decisions. In this report, the years 2018 and 2021 are considered as historical years, 2022 as the base year, 2023 as the estimated year, and years from 2024 to 2030 are considered as the forecast period.

Market Segmentation & Coverage:

The report on the Global Cellular Immunotherapy Market identifies key attributes about the customer to define the potential market and identify different needs across the industry. Understanding the potential customer group's economies and geographies can help gain business acumen for better strategic decision-making. The market coverage across different industry verticals reveals the hidden truth about the players' strategies in different verticals and helps the organization decide target audience. This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for the market plan. This research report categorizes the Global Cellular Immunotherapy Market in order to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Type, the market is studied across CAR T-Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, and Tumor-Infiltrating Lymphocytes Therapy.
  • Based on Indication, the market is studied across B-Cell Malignancies, Liver Cancer, Prostate Cancer, and Renal Cell Carcinoma.
  • Based on Technology Type, the market is studied across Cytokines & Immunomodulators and Monoclonal Antibodies.
  • Based on End-Use, the market is studied across Cancer Institutes and Hospitals.
  • Based on Region, the market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes vendors in the Global Cellular Immunotherapy Market. based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinder, N: Niche, and V: Vital). The Global Cellular Immunotherapy Market FPNV Positioning Matrix representation/visualization further aids businesses in better decision-making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market, providing the idea of revenue generation into the overall market compared to other vendors in the space. This provides insights on vendors performance in terms of revenue generation and customer base compared to others. The Global Cellular Immunotherapy Market Share Analysis offers an idea of the size and competitiveness of the vendors for the base year. The outcome reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various strategies for business growth adopted by the vendors. The news in this section covers valuable insights at various stages while keeping up with the business and engaging stakeholders in the economic debate. The Global Cellular Immunotherapy Market Competitive Scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected helps vendors understand the gaps in the marketplace and competitor’s strengths and weaknesses, providing insights to enhance products and services.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Cellular Immunotherapy Market, including Adaptimmune Therapeutics PLC, Adicet Bio, Inc, Apac Biotech Private Limited, AstraZeneca PLC, Atara Biotherapeutics, Inc., Bristol-Myers Squibb Company, Celyad Oncology SA, Dendreon Pharmaceuticals LLC, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline plc., Inovio Pharmaceuticals, Inc., Iovance Biotherapeutics, Inc., Johnson & Johnson Services, Inc., JW CreaGene Co. Ltd, JW therapeutic, Merck KGaA, Novartis AG, Pfizer Inc., and Tessa Therapeutics Ltd..

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation
5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Cellular Immunotherapy Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cellular Immunotherapy Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cellular Immunotherapy Market?
4. What is the competitive strategic window for opportunities in the Global Cellular Immunotherapy Market?
5. What are the technology trends and regulatory frameworks in the Global Cellular Immunotherapy Market?
6. What is the market share of the leading vendors in the Global Cellular Immunotherapy Market?
7. What modes and strategic moves are considered suitable for entering the Global Cellular Immunotherapy Market?
Frequently Asked Questions about the Global Cellular Immunotherapy Market

What is the estimated value of the Global Cellular Immunotherapy Market?

The Global Cellular Immunotherapy Market was estimated to be valued at $9000.43 Million in 2022.

What is the growth rate of the Global Cellular Immunotherapy Market?

The growth rate of the Global Cellular Immunotherapy Market is 25.2%, with an estimated value of $54607.77 Million by 2030.

What is the forecasted size of the Global Cellular Immunotherapy Market?

The Global Cellular Immunotherapy Market is estimated to be worth $54607.77 Million by 2030.

Who are the key companies in the Global Cellular Immunotherapy Market?

Key companies in the Global Cellular Immunotherapy Market include Adaptimmune Therapeutics PLC, Adicet Bio, Inc, Apac Biotech Private Limited, AstraZeneca PLC, Atara Biotherapeutics, Inc., Bristol, Myers Squibb Company, Celyad Oncology SA and F. Hoffmann.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Prevalence of cancer and advanced cell based therapies
5.1.1.2. Favorable government initiatives for cellular therapies R&D
5.1.1.3. Increasing prevalence for tumor-infiltrating lymphocyte (TIL) therapy and engineered T cell receptor (TCR) therapy
5.1.2. Restraints
5.1.2.1. High initial costs of devices and therapies
5.1.3. Opportunities
5.1.3.1. Technological advancements and new products for cellular immunotherapy
5.1.3.2. Increasing approvals of different cell-based immunotherapy drugs
5.1.4. Challenges
5.1.4.1. Product recalls and stringent regulatory approvals
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of Russia-Ukraine Conflict
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Threat of Substitutes
5.5.4. Threat of Substitutes
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
5.8. Client Customization

6. Cellular Immunotherapy Market, by Type
6.1. Introduction
6.2. CAR T-Cell Therapy
6.3. Dendritic Cell Therapy
6.4. NK Cell Therapy
6.5. Tumor-Infiltrating Lymphocytes Therapy

7. Cellular Immunotherapy Market, by Indication
7.1. Introduction
7.2. B-Cell Malignancies
7.3. Liver Cancer
7.4. Prostate Cancer
7.5. Renal Cell Carcinoma

8. Cellular Immunotherapy Market, by Technology Type
8.1. Introduction
8.2. Cytokines & Immunomodulators
8.3. Monoclonal Antibodies

9. Cellular Immunotherapy Market, by End-Use
9.1. Introduction
9.2. Cancer Institutes
9.3. Hospitals

10. Americas Cellular Immunotherapy Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Cellular Immunotherapy Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Cellular Immunotherapy Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Product Portfolio Analysis, By Key Player
13.5. Competitive Scenario
13.5.1. Merger & Acquisition
13.5.2. Agreement, Collaboration, & Partnership
13.5.3. New Product Launch & Enhancement
13.5.4. Investment & Funding
13.5.5. Award, Recognition, & Expansion

14. Company Usability Profiles
14.1. Adaptimmune Therapeutics PLC
14.2. Adicet Bio, Inc
14.3. Apac Biotech Private Limited
14.4. AstraZeneca PLC
14.5. Atara Biotherapeutics, Inc.
14.6. Bristol-Myers Squibb Company
14.7. Celyad Oncology SA
14.8. Dendreon Pharmaceuticals LLC
14.9. F. Hoffmann-La Roche AG
14.10. Gilead Sciences, Inc.
14.11. GlaxoSmithKline plc.
14.12. Inovio Pharmaceuticals, Inc.
14.13. Iovance Biotherapeutics, Inc.
14.14. Johnson & Johnson Services, Inc.
14.15. JW CreaGene Co. Ltd
14.16. JW therapeutic
14.17. Merck KGaA
14.18. Novartis AG
14.19. Pfizer Inc.
14.20. Tessa Therapeutics Ltd.

15. Appendix
15.1. Discussion Guide
15.2. License & Pricing


List of Figures
FIGURE 1. GLOBAL CELLULAR IMMUNOTHERAPY MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, 2022 VS 2030
FIGURE 3. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 5. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CELLULAR IMMUNOTHERAPY MARKET COMPETITIVE STRATEGIC WINDOW, BY REGION, 2030
FIGURE 7. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 8. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CELLULAR IMMUNOTHERAPY MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 10. GLOBAL CELLULAR IMMUNOTHERAPY MARKET DYNAMICS
FIGURE 11. GLOBAL CELLULAR IMMUNOTHERAPY MARKET PORTER’S FIVE FORCES ANALYSIS
FIGURE 12. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2022 VS 2030 (%)
FIGURE 13. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL CELLULAR IMMUNOTHERAPY MARKET COMPETITIVE STRATEGIC WINDOW, BY TYPE, 2030
FIGURE 15. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CAR T-CELL THERAPY, 2018-2030 (USD MILLION)
FIGURE 16. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, 2018-2030 (USD MILLION)
FIGURE 17. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY NK CELL THERAPY, 2018-2030 (USD MILLION)
FIGURE 18. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TUMOR-INFILTRATING LYMPHOCYTES THERAPY, 2018-2030 (USD MILLION)
FIGURE 19. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2022 VS 2030 (%)
FIGURE 20. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL CELLULAR IMMUNOTHERAPY MARKET COMPETITIVE STRATEGIC WINDOW, BY INDICATION, 2030
FIGURE 22. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY B-CELL MALIGNANCIES, 2018-2030 (USD MILLION)
FIGURE 23. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
FIGURE 24. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD MILLION)
FIGURE 25. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2030 (USD MILLION)
FIGURE 26. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2022 VS 2030 (%)
FIGURE 27. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 28. GLOBAL CELLULAR IMMUNOTHERAPY MARKET COMPETITIVE STRATEGIC WINDOW, BY TECHNOLOGY TYPE, 2030
FIGURE 29. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CYTOKINES & IMMUNOMODULATORS, 2018-2030 (USD MILLION)
FIGURE 30. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
FIGURE 31. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2022 VS 2030 (%)
FIGURE 32. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 33. GLOBAL CELLULAR IMMUNOTHERAPY MARKET COMPETITIVE STRATEGIC WINDOW, BY END-USE, 2030
FIGURE 34. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CANCER INSTITUTES, 2018-2030 (USD MILLION)
FIGURE 35. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
FIGURE 36. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 37. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 38. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 39. AMERICAS CELLULAR IMMUNOTHERAPY MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 40. ARGENTINA CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 41. BRAZIL CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 42. CANADA CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 43. MEXICO CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 44. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 45. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 46. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 47. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2030
FIGURE 48. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 49. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 50. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 51. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 52. AUSTRALIA CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 53. CHINA CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 54. INDIA CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 55. INDONESIA CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 56. JAPAN CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 57. MALAYSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 58. PHILIPPINES CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 59. SINGAPORE CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 60. SOUTH KOREA CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 61. TAIWAN CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 62. THAILAND CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 63. VIETNAM CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 64. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 65. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 66. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 67. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 68. DENMARK CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 69. EGYPT CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 70. FINLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 71. FRANCE CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 72. GERMANY CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 73. ISRAEL CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 74. ITALY CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 75. NETHERLANDS CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 76. NIGERIA CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 77. NORWAY CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 78. POLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 79. QATAR CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 80. RUSSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 81. SAUDI ARABIA CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 82. SOUTH AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 83. SPAIN CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 84. SWEDEN CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 85. SWITZERLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 86. TURKEY CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 87. UNITED ARAB EMIRATES CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 88. UNITED KINGDOM CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 89. GLOBAL CELLULAR IMMUNOTHERAPY MARKET: FPNV POSITIONING MATRIX, 2022
FIGURE 90. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2022
FIGURE 91. GLOBAL CELLULAR IMMUNOTHERAPY MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2022


List of Tables
TABLE 1. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CAR T-CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY NK CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY NK CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY NK CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TUMOR-INFILTRATING LYMPHOCYTES THERAPY, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TUMOR-INFILTRATING LYMPHOCYTES THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TUMOR-INFILTRATING LYMPHOCYTES THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY B-CELL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY B-CELL MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY B-CELL MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CYTOKINES & IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CYTOKINES & IMMUNOMODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CYTOKINES & IMMUNOMODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CANCER INSTITUTES, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CANCER INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CANCER INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 52. ARGENTINA CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 53. ARGENTINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 54. ARGENTINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 55. ARGENTINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 56. ARGENTINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 57. BRAZIL CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 58. BRAZIL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 59. BRAZIL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 60. BRAZIL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 61. BRAZIL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 62. CANADA CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 63. CANADA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 64. CANADA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 65. CANADA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 66. CANADA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 67. MEXICO CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 68. MEXICO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 69. MEXICO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 70. MEXICO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 71. MEXICO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 78. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 79. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 80. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 81. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 82. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 83. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 84. AUSTRALIA CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 85. AUSTRALIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 86. AUSTRALIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 87. AUSTRALIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 88. AUSTRALIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 89. CHINA CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 90. CHINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 91. CHINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 92. CHINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 93. CHINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 94. INDIA CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 95. INDIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 96. INDIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 97. INDIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 98. INDIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 99. INDONESIA CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 100. INDONESIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 101. INDONESIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 102. INDONESIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 103. INDONESIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 104. JAPAN CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 105. JAPAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 106. JAPAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 107. JAPAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 108. JAPAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 109. MALAYSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 110. MALAYSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 111. MALAYSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 112. MALAYSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 113. MALAYSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 114. PHILIPPINES CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 115. PHILIPPINES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 116. PHILIPPINES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 117. PHILIPPINES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 118. PHILIPPINES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 119. SINGAPORE CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 120. SINGAPORE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 121. SINGAPORE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 122. SINGAPORE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 123. SINGAPORE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 124. SOUTH KOREA CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 125. SOUTH KOREA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 126. SOUTH KOREA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 127. SOUTH KOREA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 128. SOUTH KOREA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 129. TAIWAN CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 130. TAIWAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 131. TAIWAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 132. TAIWAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 133. TAIWAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 134. THAILAND CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 135. THAILAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 136. THAILAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 137. THAILAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 138. THAILAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 139. VIETNAM CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 140. VIETNAM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 141. VIETNAM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 142. VIETNAM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 143. VIETNAM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 150. DENMARK CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 151. DENMARK CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 152. DENMARK CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 153. DENMARK CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 154. DENMARK CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 155. EGYPT CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 156. EGYPT CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 157. EGYPT CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 158. EGYPT CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 159. EGYPT CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 160. FINLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 161. FINLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 162. FINLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 163. FINLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 164. FINLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 165. FRANCE CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 166. FRANCE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 167. FRANCE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 168. FRANCE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 169. FRANCE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 170. GERMANY CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 171. GERMANY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 172. GERMANY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 173. GERMANY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 174. GERMANY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 175. ISRAEL CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 176. ISRAEL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 177. ISRAEL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 178. ISRAEL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 179. ISRAEL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 180. ITALY CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 181. ITALY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 182. ITALY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 183. ITALY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 184. ITALY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 185. NETHERLANDS CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 186. NETHERLANDS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 187. NETHERLANDS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 188. NETHERLANDS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 189. NETHERLANDS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 190. NIGERIA CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 191. NIGERIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 192. NIGERIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 193. NIGERIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 194. NIGERIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 195. NORWAY CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 196. NORWAY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 197. NORWAY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 198. NORWAY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 199. NORWAY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 200. POLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 201. POLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 202. POLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 203. POLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 204. POLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 205. QATAR CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 206. QATAR CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 207. QATAR CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 208. QATAR CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 209. QATAR CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 210. RUSSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 211. RUSSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 212. RUSSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 213. RUSSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 214. RUSSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 215. SAUDI ARABIA CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 216. SAUDI ARABIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 217. SAUDI ARABIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 218. SAUDI ARABIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 219. SAUDI ARABIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 220. SOUTH AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 221. SOUTH AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 222. SOUTH AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 223. SOUTH AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 224. SOUTH AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 225. SPAIN CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 226. SPAIN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 227. SPAIN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 228. SPAIN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 229. SPAIN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 230. SWEDEN CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 231. SWEDEN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 232. SWEDEN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 233. SWEDEN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 234. SWEDEN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 235. SWITZERLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 236. SWITZERLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 237. SWITZERLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 238. SWITZERLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 239. SWITZERLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 240. TURKEY CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 241. TURKEY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 242. TURKEY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 243. TURKEY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 244. TURKEY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 245. UNITED ARAB EMIRATES CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 246. UNITED ARAB EMIRATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 247. UNITED ARAB EMIRATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 248. UNITED ARAB EMIRATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 249. UNITED ARAB EMIRATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 250. UNITED KINGDOM CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 251. UNITED KINGDOM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 252. UNITED KINGDOM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 253. UNITED KINGDOM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 254. UNITED KINGDOM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 255. GLOBAL CELLULAR IMMUNOTHERAPY MARKET: FPNV POSITIONING MATRIX - SCORES, 2022
TABLE 256. GLOBAL CELLULAR IMMUNOTHERAPY MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2022
TABLE 257. GLOBAL CELLULAR IMMUNOTHERAPY MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2022
TABLE 258. GLOBAL CELLULAR IMMUNOTHERAPY MARKET RANKING, BY KEY PLAYER, 2022
TABLE 259. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2022
TABLE 260. GLOBAL CELLULAR IMMUNOTHERAPY MARKET PRODUCT PORTFOLIO ANALYSIS, BY KEY PLAYER, 2022
TABLE 261. GLOBAL CELLULAR IMMUNOTHERAPY MARKET MERGER & ACQUISITION
TABLE 262. GLOBAL CELLULAR IMMUNOTHERAPY MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 263. GLOBAL CELLULAR IMMUNOTHERAPY MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 264. GLOBAL CELLULAR IMMUNOTHERAPY MARKET INVESTMENT & FUNDING
TABLE 265. GLOBAL CELLULAR IMMUNOTHERAPY MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 266. GLOBAL CELLULAR IMMUNOTHERAPY MARKET: LICENSE & PRICING

Companies Mentioned

  • Adaptimmune Therapeutics PLC
  • Adicet Bio, Inc
  • Apac Biotech Private Limited
  • AstraZeneca PLC
  • Atara Biotherapeutics, Inc.
  • Bristol-Myers Squibb Company
  • Celyad Oncology SA
  • Dendreon Pharmaceuticals LLC
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc.
  • Inovio Pharmaceuticals, Inc.
  • Iovance Biotherapeutics, Inc.
  • Johnson & Johnson Services, Inc.
  • JW CreaGene Co. Ltd
  • JW therapeutic
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Tessa Therapeutics Ltd.

Methodology

Loading
LOADING...